Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
International Sweetene...International Sweetener Colloquium
Not Confirmed
Not Confirmed
22-25 February, 2026
Not Confirmed
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Not Confirmed
Not Confirmed
24-25 February, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
International Sweetene...International Sweetener Colloquium
Industry Trade Show
Not Confirmed
22-25 February, 2026
Industry Trade Show
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Industry Trade Show
Not Confirmed
24-25 February, 2026
Digital content

17 Feb 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nuvation-bio-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-2-2026-302688141.html

09 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260204350848/en/Nuvation-Bio-Announces-Pivotal-Global-Phase-3-SIGMA-Trial-G203-for-Safusidenib-in-IDH1-Mutant-Glioma

12 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260111551486/en/Nuvation-Bio-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Outlook-Ahead-of-44th-Annual-J.P.-Morgan-Healthcare-Conference

12 Jan 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-01-12/nuvation-bio-and-eisai-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-addi

06 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260106957073/en/Nuvation-Bio-to-Present-at-the-44th-Annual-J.P.-Morgan-Healthcare-Conference

03 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251203703470/en/Nuvation-Bio-Announces-Publication-of-Positive-Phase-2-Study-Results-for-Safusidenib-for-the-Treatment-of-Grade-2-IDH1-Mutant-Glioma-in-Neuro-Oncology
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE